The EORTC GastroIntestinal Tract Cancer Group and the EORTC HeadQuarters wish to set up a European screening platform for advanced colo-rectal cancer (CRC) patients. The goal of this screening platform is to provide quick access to new drugs to patients by offering a new structure for clinical trials. Currently some of the most challenging clinical questions arise from the molecular sub-division of CRC that would theoretically allow to inhibit the specific, altered pathways in the patients. A major problem for trials in this "personalized medicine" is that the low frequency of the different mutations requires a high effort for screening and identifying the patients. The EORTC CRC screening platform will hopefully offer a feasible and efficient way to characterize the patients on the molecular basis of their tumors and allow to offer them rapid and preferential participation in clinical studies with new drugs targeted to their specific pathway alterations.
Study Type
OBSERVATIONAL
Enrollment
668
Tumour markers testing in patients advanced or metastatic colo-rectal cancer.
Hopitaux Universitaires Bordet-Erasme - Institut Jules Bordet
Brussels, Belgium
Hopitaux Universitaires Bordet-Erasme - Hopital Universitaire Erasme
Brussels, Belgium
Cliniques Universitaires Saint-Luc
Brussels, Belgium
Universitair Ziekenhuis Antwerpen
Edegem, Belgium
U.Z. Leuven - Campus Gasthuisberg
Leuven, Belgium
Tumour markers assessment
Five basic tumour markers will be tested: Kras, nras, braf, MSI and PKI3
Time frame: Within 1 week after patient registration
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Bank Of Cyprus Oncology Centre
Stróvolos, Cyprus
Gustave Roussy Cancer Campus
Villejuif, France
Universitaetsklinikum Carl Gustav Carus
Dresden, Germany
Universitaets-Krankenhaus Eppendorf
Hamburg, Germany
Universitaetsklinikum Leipzig
Leipzig, Germany
...and 17 more locations